Diamyd Medical AB (FRA:DMN) Net Income (Continuing Operations): €-26.08 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
40 GF Score
Price €0.08
GF Value €0.07
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Net Income (Continuing Operations)?

Diamyd Medical AB FRA:DMN +11.49% 40 Net Income (Continuing Operations) is €-26.08 Mil as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 40/100 and a GF Value™ of €0.07 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Diamyd Medical AB's Net Income (Continuing Operations) for the three months ended in May. 2026 was €-11.70 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in May. 2026 was €-26.08 Mil.

Diamyd Medical AB  (FRA:DMN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Diamyd Medical AB Net Income (Continuing Operations) Related Terms

Diamyd Medical AB Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Net Income (Continuing Operations) Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.88 -9.85 -9.83 -13.26 -15.23

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.03 -4.02 -4.44 -5.92 -11.70
FRA:DMN
40GF Score
Diamyd Medical AB FRA:DMN
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-26.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €-26.08 Mil mean?
Diamyd Medical AB (FRA:DMN) has a Net Income (Continuing Operations) of €-26.08 Mil as of May. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Net Income (Continuing Operations) too high?
Diamyd Medical AB's current Net Income (Continuing Operations) is €-26.08 Mil. Overall, Diamyd Medical AB has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Net Income (Continuing Operations) compare to VRTX and REGN?
Diamyd Medical AB's Net Income (Continuing Operations) of €-26.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Net Income (Continuing Operations) is €-26.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.08 — trading 12.3% above its estimated fair value. The current Net Income (Continuing Operations) is €-26.08 Mil. Diamyd Medical AB's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Net Income (Continuing Operations) is €-26.08 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.08 is trading 12.3% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Modestly Overvalued.

Key valuation signals for FRA:DMN:

  • Net Income (Continuing Operations): €-26.08 Mil
  • GF Value™: €0.07 vs. price of €0.08 (12.3% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
40GF Score

Get the complete analysis for FRA:DMN

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.07
GF Value